Is hydroxychloroquine beneficial for COVID-19 patients?

Xing Li, Ying Wang, Patrizia Agostinis, Arnold Rabson, Gerry Melino, Ernesto Carafoli, Yufang Shi, Erwei Sun

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world1–3, the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 20204. The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir5, to control the disease and halt the pandemic.

Original languageEnglish (US)
Article number512
JournalCell Death and Disease
Issue number7
StatePublished - Jul 1 2020

All Science Journal Classification (ASJC) codes

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research


Dive into the research topics of 'Is hydroxychloroquine beneficial for COVID-19 patients?'. Together they form a unique fingerprint.

Cite this